OMEPRAZOLE EXTENDED-RELEASE CAPSULES

The Defense Logistics Agency awarded a fixed-price delivery order, SPE2DP-26-F-7672, to DMS Pharmaceutical Group Inc. (CAGE 1UNB0), a small, small disadvantaged, and women-owned small business, for the procurement of eight blister pack units of OMEPRAZOLE EXTENDED-RELEASE CAPSULES under the master contract SPE2DX-25-D-9900. The total contract value is $348.80, with delivery required by July 14, 2026, to Fort Lewis, WA, under FOB Destination terms, meaning the contractor bears all risk and responsibility until the product arrives at the delivery point. The item is identified by NSN 6505013142716 and NDC code 00186-0742-31, conforming to FDA regulatory standards and DoD unit of issue requirements. Packaging must be shipped via traceable means—excluding parcel post—with all packages labeled with the full delivery address as specified per the MARKFOR field, though no specific packaging materials, preservation methods, or barcoding standards are detailed. Inspection and acceptance occur at the destination by the Government, with no formal inspection criteria beyond contractual compliance cited. Payment will be processed by the Defense Finance and Accounting Service in Columbus, OH, using appropriation identifier 97X4930 5CBX 001 2620 S33189 and program requirement 7017505547, with the contracting officer Lisa Quinn and administrator Shairy M. Cartagena identified for administrative support. No Contracting Officer’s Representative is named, and no specific FAR or DFARS clauses, attachments, evaluation factors, or special requirements are documented, reflecting a streamlined acquisition of a standard commercial pharmaceutical item consistent with a Lowest Price Technically Acceptable approach. The contractor’s small business certifications remain active and subject to compliance verification under applicable small business programs.